The COVID-19 pandemic marks the third coronavirus pandemic this century (SARS-CoV-1,
MERS, SARS-CoV-2), emphasizing the need to identify and evaluate conserved …

The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this
global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster than …

Recent studies have reported the protective efficacy of both natural 1 and vaccine-induced
2 , 3 , 4 , 5 , 6 – 7 immunity against challenge with severe acute respiratory syndrome …

The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has made the development of a vaccine a top …

A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
may be required to end the coronavirus disease 2019 (COVID-19) pandemic 1 , 2 , 3 , 4 …

An understanding of protective immunity to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is critical for vaccine and public health strategies aimed at ending the global …

Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some
individuals develop severe pneumonia, respiratory failure and death 1 , 2 , 3 – 4 . Studies of …

Respiratory virus challenge studies involve administration of the challenge virus and sampling
to assess for protection in the same anatomical locations. It can therefore be difficult to …

Malassezia are a monophyletic phylum of 18 species of commensal/ pathogenic yeasts that
are prominent in the mammalian mycobiome, and recently linked to risk of Crohn’s Disease. …

In the print version of this Article, some of the symbols were corrupted in Fig. 6. The HTML
and PDF versions of the Article were correct, and so the original Article has not been …